External validation of the BRIGHT-4 results shows that patients with ST-segment myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI) who receive bivalirudin plus a high-dose infusion 2- to 4-hours post-PCI have reduced cardiac mortality and major bleeding, and no increase in ischemic events, compared with patients who receive heparin monotherapy with provisional glycoprotein IIb/IIIa inhibitor (GPI) use. 

Findings from a new study reveal an association between higher guideline-directed medical therapy (GDMT) score at discharge with lower mortality, hospitalization, more home time and lower costs. 

Late gadolinium enhancement (LGE) was a risk factor for sudden cardiac death (SCD) in children and adolescents with hypertrophic cardiomyopathy (HCM), a new international retrospective cohort study shows.

Well-being is inversely related to cardiovascular disease (CVD) risk, according to results from a UK Biobank analysis.

A case report of a woman presenting with electrocardiogram (ECG) shark-fin phenomenon caused by subarachnoid hemorrhage “underscores the significance of meticulous clinical assessment” for ST-segment changes and the inclusion of intracranial pathology in the differential diagnosis, warns a new case report.

A newly-published review is calling for more randomized trials to be carried out in order to further strengthen the relationship between obstructive sleep apnea (OSA) and cardiovascular mortality.

Randomized control trials (RCTs) do not show long-term benefits of continuous positive airway pressure (CPAP) devices on cardiovascular outcomes, say researchers, who point out post-hoc analyses demonstrates improved outcomes in those who use CPAP adequately. 

Administering a new high-sensitivity cardiac troponin test (hs-cTn) bedside to emergency department (ED) patients, with a 0/1-hour diagnostic algorithm, moderately reduces ED length of stay and is just as safe as centralized testing, results from the WESTCOR-POC trial show. 

Undergoing percutaneous coronary intervention (PCI) for narrowed arteries with a novel bioadaptor has clinical non-inferiority and offers a significant reduction in adverse clinical events than a contemporary drug-eluting stent (DES), according to new data from the INFINITY-SWEDEHEART trial.